What is the efficacy of torsemide tablets and what happens if there is an overdose of the drug

Imagi Torsemide Tablets Torsemide tablets are widely preferred by patients with cardiovascular and cerebrovascular diseases, and torsemide tablets have many functions and have made great contributions to the medical community. Torsemide tablets are a popular drug for cardiovascular and cerebrovascular diseases, so what is the efficacy of torsemide tablets? What happens if you overdose?

Indications for torsemide tablets (terthromine): for patients with congestive heart failure, cirrhosis ascites, and edema caused by kidney disease; It can also be used in patients with essential hypertension. The effect is more significant, the reputation is very good, and those who have used it like it very much.

There have been no reports of overdose of torsemide tablets, but if you overdose on imagi (torsemide tablets), the main symptoms are expected to be: dehydration, volume depletion, hypotension, hyponatremia, hypokalemia, hypochloremic alkalosis, and hemoconcentration. Overdose of torsemide tablets should be followed by rehydration and electrolyte replacement.

Laboratory methods for determining the clear concentration of its metabolites in torsemide tablets have not been widely used. There are no data to suggest that some physiological means, such as adjusting the pH of the urine, can promote the elimination of torsemide tablets and their metabolites. Hemodialysis does not remove torsemide tablets.

Patients are advised to take it under the guidance of a doctor and consult a doctor as soon as possible if they feel unwell.

Torsemide tablets are white tablets. Tolesemide tablets indications 1edema due to congestive heart failure; 2.Essential hypertension.

When torsemide tablets are overdosed, the loss of fluids and electrolytes can lead to drowsiness, electrolyte imbalances, and gastrointestinal symptoms. Treatment: symptomatic and supportive**, timely replenishment of body fluids and electrolytes, and dynamic monitoring of electrolytes.

Torsemide tablets should be available through formal channels (eg:Cardinal Health's PharmacyGo buy it! In order to avoid being deceived and buying fake medicines!

Torsemide tablets.

Indications]:

It is used for patients with congestive heart failure, cirrhosis ascites, and edema caused by kidney disease; It can also be used in patients with essential hypertension.

Furosemide. Indications]:

1.Edematous disorders include congestive heart failure, cirrhosis, kidney disease (nephritis, nephropathy, and acute and chronic renal failure of various causes), especially if other diuretics do not respond well. Combined with other drugs**Acute pulmonary edema and acute cerebral edema, etc.

2.Hypertension is generally not used as the first choice for essential hypertension, but it is particularly suitable when thiazides are not effective, especially when accompanied by renal insufficiency or hypertensive crisis. 3.

Prevention of acute renal failure is used for renal hypoperfusion due to various causes, such as dehydration, shock, poisoning, anesthesia accidents, and circulatory insufficiency, etc., and timely application while correcting volume depletion can reduce the chance of acute tubular necrosis. 4.Hyperkalemia and.

Torsemide is good and has little effect on electrolytes.

Torsemide. Common adverse reactions include headache, dizziness, fatigue, loss of appetite, muscle cramps, nausea and vomiting, hyperglycemia, hyperuricemia, constipation and diarrhea; Long-term heavy use may cause water and electrolyte balance to lose sail and deregulation. **Polyuria is common in patients with early and older state knowledge, and individual patients with hypotension, mental disorders, thrombotic complications and heart rhythm disorders caused by cardiac or cerebral ischemia, angina, acute myocardial infarction or fainting due to hemoconcentration, hypokalemia can occur in patients with hypokalemic diet, vomiting, diarrhea, excessive use of laxatives and abnormal liver function.

Individual patients may have ** allergies, occasional itching, rash, photosensitivity reactions, rare dry mouth, limb paresthesias, and visual impairment.

Hello, the main ingredient of torsemide tablets is torsemide, which enjoys a good reputation among consumers because of its remarkable effect in congestive heart failure, liver cirrhosis, abdominal slippery huiqing water, edema patients caused by kidney disease and essential hypertension. Torsemide tablets can increase the concentration of sodium chloride in the luminal fluid, increase the osmotic pressure, reduce the sodium chloride in the renal medullary fluid, and decrease the osmotic pressure gradient, thereby interfering with the urine concentration process and increasing the excretion of urine sodium and chloride ions and water. Bi Qian.

The adverse reactions of torsemide include headache, dizziness, fatigue, loss of appetite, muscle cramps, nausea and vomiting, hyperglycemia, hyperuricemia, constipation and diarrhea, while spironolactone's *** is hyperkalemia, nausea and vomiting, stomach cramps, diarrhea, peptic ulcer, pay attention to recheck blood potassium. Those with renal failure should not take it.

1. Patients with essential hypertension will combine this product with receptor blockers, ACE inhibitors and calcium channel blockers, and patients with congestive heart failure will combine this product with digitoxin, ACE inhibitors and nitrates, and no new or unexpected adverse reactions will be found. 2. This product has no effect on the binding rate of glibenclamide, warfarin and plasma proteins, no effect on the anticoagulant effect of phenylprocoumarin (related coumarin derivative), and no effect on the pharmacokinetics of digoxin or carvedilol (vasodilator, receptor blocker). Healthy volunteers combined this product with spironolactone, the renal clearance rate of the latter decreased, and the AUC value increased, but clinical experience showed that there was no need to adjust the dose of the two drugs.

3. Because salicylic acid drugs compete with this product for renal tubular secretion, the toxicity of salicylic acid can be observed in the high-dose group after combining with this product. Although the drug interaction between this product and non-steroidal anti-inflammatory drugs has not been studied, the combination of the above drugs with furosemide can occasionally cause renal dysfunction. 4. Like many diuretics, indomethacin will partially inhibit the excretion of urinary sodium of this product.

This phenomenon was observed in patients with sodium restriction (50 mEq days) but not in patients with normal sodium uptake (150 mEq days). 5. Cimetidine and spironolactone have no effect on the pharmacokinetics and diuretic effect of this product. Taking digoxin at the same time can increase the AUC value of this product by 50%, but there is no need to adjust the dose of this product.

6. The human drug interaction between the combination of this product and cholestyramine has not been studied, but in animal tests, cholestyramine reduces the absorption rate of oral use of this product, and the combination of the two drugs is not recommended. 7. Taking probenecid at the same time reduces the amount secreted into the proximal convoluted tubules, and the diuretic effect of this product decreases. 8. It is known that other diuretics can reduce the renal clearance rate of lithium and increase the risk of lithium toxicity, so the combination of the two types of drugs must be cautious.

The drug interaction between this product and lithium has not been studied. 9. Other diuretics can increase the potential ototoxicity of aminoglycoside antibiotics and etanic acid, especially in patients with renal impairment, and the interaction between this product and the above drugs has not been studied.

Oral, starting with lomg once a day, can be increased to 2 omg once a day as needed.

The safety of this product was evaluated in about 4,000 patients: 800 cases used this product for at least 6 months, and more than 380 cases were more than 1 year. Among these patients, 564 patients underwent clinical trials of this product in the United States, and 274 cases were used as blank controls.

The *** of this product is usually transient and does not correlate with age, gender, ethnicity or course of treatment. The incidence of interruption due to *** was in the United States), while the control group was. In the United States and Europe, the rate of discontinuation in patients with congestive heart failure is ***, while furosemide is; The discontinuation rate for patients with renal insufficiency is as follows: The discontinuation rate for patients with cirrhosis is 0% furosemide.

The most common factors for discontinuation of this product are (in descending order): dizziness, headache, nausea, weakness, vomiting, hyperglycemia, excessive urination, hypokalemia, severe dry mouth, hypovolemia, impotence, esophageal bleeding, and dyspepsia. Because of these, the *** exit rate is between.

More than 1% of the primary controlled studies conducted in the United States that were likely or probable to be related to the drug were: headache, excessive urination, dizziness, rhinitis, fatigue, diarrhea, electrocardiogram, cough, constipation, nausea, arthralgia, dyspepsia, sore throat, muscle pain, chest pain, insomnia, edema, and nervousness. In these clinical trials, the daily dose range of this product was that most patients took 5mg lomg for a course of 1 52 days, with an average of 41 days.

Only the incidence of excessive urination was higher in the Torsemide group than in the control group. In controlled studies of hypertensive disorders, the incidence of excessive urination was 1% in the control group, 4% in torsemide 5 mg days, and 15% in lomg days. Excessive urination was not reported as a side reaction event in patients with heart failure and liver and kidney insufficiency who received this product.

Drug-related serious adverse reactions that cannot be ruled out in clinical studies are: atrial fibrillation, chest pain, diarrhea, digitalis poisoning, gastrointestinal bleeding, hyperglycemia, hyperuricemia, hypokalemia, hypotension, hypovolemia, thrombosis, rash, rectal bleeding, syncope, and tachycardia. There was a report of a patient who developed angioedema after using this product, and it was later found that the person was allergic to sulfonamides.

According to the clinical control study, the drug correlation evaluation was not carried out, and the tolasemide group was larger than the control group for arthritis and other non-specific musculoskeletal problems, but the gout in the control group was greater than that in the torsemide group. The incidence and severity of these *** are not related to the dose of torsemide. One patient stopped taking this product due to myalgia, and one patient in the control group stopped taking the drug due to gout.

Hypokalemia: see Precautions.

1. Patients who are known to be allergic to torsemide or sulfonylureas are prohibited from using this product. 2. Patients with anuria are prohibited from using this product.